Skip to main content
OpenTrials
Completed

NCT Number: NCT02176356

Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)

A study to evaluate patient satisfaction, aesthetic and psychological impact of combined treatment with BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM® ULTRA XC, JUVÉDERM® ULTRA PLUS XC, JUVÉDERM® VOLUMA® XC, and LATISSE® (bimatoprost ophthalmic solution).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Facial Rhytides Crow's Feet Lines Glabellar Lines Nasolabial Fold

Age range

35 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Los Angeles, California, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Qualified to receive treatment with BOTOX® Cosmetic, a facial filler (JUVÉDERM® ULTRA XC and/or JUVÉDERM® ULTRA Plus XC and/or JUVÉDERM® VOLUMA® XC) and LATISSE® treatment
  • Naïve to botulinum toxin therapy of any serotype for any indication
  • Naïve to prescription eyelash growth products of any type
  • Naïve to dermal filler treatment in the face and neck

Exclusion criteria

  • Undergone facial plastic surgery, tissue grafting, tissue augmentation or facial dermal filler injections
  • Had laser, photomodulation, intense pulsed light, radio frequency, dermabrasion or chemical peel in the face or neck
  • Have received skin resurfacing (laser, photomodulation, intense pulsed light, radio frequency, dermabrasion, chemical peel, or non-ablative procedures) in the face or neck within 3 months
  • Systemic retinoid therapy within 1 year prior to study enrollment
  • Presence of inflammation at the proposed injection site(s)
  • Profound atrophy/excessive weakness of muscles in target areas of injection
  • Known immunization or hypersensitivity to any botulinum toxin serotype
  • Undergone oral surgery or dental procedures within 30 days
  • No visible eyelashes
  • Use of permanent eyeliner, eyelash implants, semi-permanent eyelash tint, dye or extension
  • Use of prescription eyelash growth products
  • Unwilling or unable to remove contact lenses prior to study medication application in the evening and keep lenses out for 30 minutes
  • Diagnosis of myasthenia gravis, Eaton-Lambert Syndrome, amyotrophic lateral sclerosis, or any other disease that might interfere with neuromuscular function.

Treatment and study plan

onabotulinumtoxinA

Biological

onabotulinumtoxinA (BOTOX® Cosmetic) 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas.

Other names: botulinum toxin Type A

bimatoprost ophthalmic solution 0.03%

Drug

bimatoprost ophthalmic solution 0.03% (LATISSE®) 1 drop applied to the upper eyelid at the base of eyelashes once daily in the evening for 17 weeks.

Other names: LATISSE®

JUVÉDERM® ULTRA XC

Device

JUVÉDERM® ULTRA XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.

JUVÉDERM® ULTRA PLUS XC

Device

JUVÉDERM® ULTRA PLUS XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.

JUVÉDERM® VOLUMA® XC

Device

JUVÉDERM® VOLUMA® XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.

Primary outcomes

  1. Change From Baseline in Satisfaction With Facial Appearance Overall Using a 10-item Questionnaire

    Time frame: Baseline, Month 4

    Participants assessed their satisfaction with the way they look right now with their entire face in mind using a 10-item questionnaire. Possible responses to each question were: 1=Very dissatisfied, 2=Somewhat dissatisfied, 3-=Somewhat satisfied and 4=Very satisfied. The responses were added across items and transformed to a Rasch scale ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement.

Secondary outcomes

  1. Change From Baseline in Aging Appearance Using a 7-item Questionnaire

    Time frame: Baseline, Month 4

    Participants rated how they look now using a 7-item questionnaire. Possible responses for each question are 1=Definitely disagree, 2=Somewhat disagree, 3=Somewhat agree or 4=Definitely agree. The responses were added across items and transformed to a Rasch score ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement.

  2. Change From Baseline in Age Appraisal Using a Visual Analogue Scale (VAS)

    Time frame: Baseline, Month 4

    Participants assessed how old they think they look compared to their actual age using a VAS by placing a mark on a number on a horizontal line where the far left of the line= -15 (look 15 years younger), 0=look current age, to the far right of the line=15 (look 15 years older). A positive change from Baseline indicates improvement.

  3. Change From Baseline in Social Confidence Using an 8-item Questionnaire

    Time frame: Baseline, Month 4

    Participants assessed their social confidence with their facial appearance in mind in the past week using an 8-item questionnaire. Possible responses for each question are 1=Definitely disagree, 2=Somewhat disagree, 3=Somewhat agree or 4= Definitely agree. The responses were added across items and transformed to a Rasch score ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement.

  4. Change From Baseline in Psychological Well-Being Using a 10-item Questionnaire

    Time frame: Baseline, Month 4

    Participants assessed their psychological well-being with their facial appearance in mind using a 10-item questionnaire. Possible responses for each question are 1=Definitely disagree, 2=Somewhat disagree, 3=Somewhat agree or 4= Definitely agree. The responses were added across items and transformed to a Rasch score ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement.

  5. Participant's Self- Perception of Age (SPA)

    Time frame: Baseline, Month 4

    Participants assessed SPA by answering the question: How do you think your facial appearance looks compared to your age today? Participants recorded how many years younger or older they thought their facial appearance made them look. A negative result indicates improvement (a younger appearance).

  6. Change From Baseline in Investigator's Assessment of Severity of Glabellar Lines (GLs) at Maximum Frown Using the Facial Wrinkle Scale (FWS)

    Time frame: Baseline, Month 4

    The investigator assessed the severity of the participant's GLs using the 4-point FWS where: 0=None, 1=Mild, 2=Moderate or 3=Severe. A negative change from Baseline indicates improvement.

  7. Change From Baseline in Investigator's Assessment of the Severity of Crow's Feet Lines (CFLs) at Maximum Smile Using the FWS

    Time frame: Baseline, Month 4

    The investigator assessed the severity of the participant's CFLs using the 4-point FWS where: 0=None, 1=Mild, 2=Moderate or 3=Severe. A negative change from Baseline indicates improvement.

  8. Change From Baseline in Investigator's Global Eyelash Assessment Score (GEAS)

    Time frame: Baseline, Month 4

    The investigator assessed the participant's eyelash prominence using the 4-point GEAS where: 1=Minimal (worst), 2=Moderate, 3=Marked and 4=Very Marked (best). A positive change from Baseline indicates improvement.

  9. Change From Baseline in the Investigator's Assessment of the Participant's Overall Mid-Face Volume Deficit Using the 6-Point MFVDS

    Time frame: Baseline, Month 4

    The investigator assessed overall mid-face volume deficit using the Mid-face Volume Deficit Scale (MFVDS) where: 0=None (moon face; fullness) [best], 1=Minimal (flattening), 2=Mild (mild concavity), 3=Moderate (moderate concavity, 4=Significant (significant concavity) and 5=Severe (wasting) [worst]. A negative change from Baseline indicates improvement.

  10. Change From Baseline in the Investigator's Assessment of the Participant's Nasolabial Folds Severity

    Time frame: Baseline, Month 4

    The investigator assessed the participants nasolabial folds severity using the 5-Point Nasolabial Fold Severity (NLFS) Scale where: 0=None (no wrinkles) [best], 1=Mild (shallow, just perceptible wrinkle), 2=Moderate (moderately deep wrinkle), 3=Severe (deep wrinkle) or 4= Extreme (very deep wrinkle). A negative change from Baseline indicates improvement.

  11. Change From Baseline in the Investigator's Assessment of the Participant's Oral Commissures Severity

    Time frame: Baseline, Month 4

    The investigator assessed the participant's oral commissure using the 4-Point Oral Commissure Severity Scale (OCSS) where: 0=None, 1=Mild, 2=Moderate or 3=Severe. A negative change from Baseline indicates improvement.

  12. Change From Baseline in the Investigator's Assessment of the Participant's Perioral Lines Severity

    Time frame: Baseline, Month 4

    The investigator assessed the participant's perioral lines severity using the 4-Point Perioral Lines at Rest Severity Scale (POLSS) where: 0=None (no lines) [best], 1=Mild (few, shallow lines), 2=Moderate (some moderate lines) or 3=Severe (many deep lines or crevices)[worst]. A negative change from Baseline indicates improvement.

  13. Change From Baseline in the Participant Satisfaction With Appearance of Periorbital Area

    Time frame: Baseline, Month 4

    Participants assessed how their overall eye appearance has affected them over the past 7 days using the 9-item Periorbital Aesthetic Appearance Questionnaire (PAAQ). Possible responses to each question were: 0=Never (best), 1=Rarely, 2=Some of the time, 3=Most of the time and 4=All of the time with a total possible score of 0 to 36. A negative change from Baseline indicates improvement.

Sponsors and collaborators

Lead sponsor

Allergan

Industry

Registry information

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Jun 27, 2014
Registry last updated
Jan 9, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.